2021
DOI: 10.1136/thoraxjnl-2021-217325
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide. Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1–2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. T… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
33
0
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 71 publications
(35 citation statements)
references
References 10 publications
(27 reference statements)
0
33
0
2
Order By: Relevance
“…The focus on two biomarkers to predict the modifiable risk of asthma attacks is novel compared with existing clinical prediction models,2–13 where prognostic variables do not include nor adjust for blood eosinophils and FeNO. The established mechanistic, prognostic (ie, predicting adverse outcomes) and theragnostic (ie, predicting treatment responsiveness) values of these type-2 inflammatory biomarkers17–24 26 provide a strong basis for a clinical prediction model centred on these independent, additive, and, most importantly, modifiable risk factors. The current protocol extends our previous proof-of-concept23 24 work suggesting that traditional clinical risk factors can and should be adjusted for type-2 inflammatory biomarkers.…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…The focus on two biomarkers to predict the modifiable risk of asthma attacks is novel compared with existing clinical prediction models,2–13 where prognostic variables do not include nor adjust for blood eosinophils and FeNO. The established mechanistic, prognostic (ie, predicting adverse outcomes) and theragnostic (ie, predicting treatment responsiveness) values of these type-2 inflammatory biomarkers17–24 26 provide a strong basis for a clinical prediction model centred on these independent, additive, and, most importantly, modifiable risk factors. The current protocol extends our previous proof-of-concept23 24 work suggesting that traditional clinical risk factors can and should be adjusted for type-2 inflammatory biomarkers.…”
Section: Discussionmentioning
confidence: 99%
“…The established mechanistic, prognostic (ie, predicting adverse outcomes) and theragnostic (ie, predicting treatment responsiveness) values of these type-2 inflammatory biomarkers17–24 26 provide a strong basis for a clinical prediction model centred on these independent, additive, and, most importantly, modifiable risk factors. The current protocol extends our previous proof-of-concept23 24 work suggesting that traditional clinical risk factors can and should be adjusted for type-2 inflammatory biomarkers. Another novel aspect of our project is our intention to collaborate with a wide variety of authors and sponsors to form an international, data-driven, and not-for-profit consortium to support the development and validation of a robust clinical prediction model.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations